Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tirzepatide also leads to greater weight loss than semaglutide for people with type 2 diabetes 14 and than liraglutide for people with obesity.15”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“In the STEP-8 trial, 70 semaglutide 2•4 mg/week led to greater weight loss (a 15•8% reduction) compared with liraglutide 3•0 mg once daily (a 6•4% reduction); in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7%”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“in the SURMOUNT-5 trial, 15 tirzepatide 15 mg caused significantly higher weight reduction (20•2%) compared with semaglutide 2•4 mg (13•7% )”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“Similar differences in effectiveness are found when looking at reductions in waist circumference, systolic blood pressure, and serum triglycerides, with differences in effect sizes reflecting the differences in weight loss in response to liraglutide, semaglutide, and tirzepatide treatment.15,70”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [15]
In the citing paper
“The efficacy of GLP-1 receptor agonists (GLP-1 RAs) in older adults has been robustly demonstrated in randomized controlled trials (RCTs) [34], providing strong evidence for their use in managing obesity and related comorbidities in individuals aged over 65.”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [34]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Self-citationTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Cited by
Items 401–500 of 590
GLP-1 Receptor Agonists in Recurrent Weight Gain after Metabolic Bariatric Surgery
Manyari, Á. A. O., & Manyari, A. L. A. A. A. J. D. O. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016875
Brož, J., Koželuhová, M., Michalec, J., & Lukáč, O. (2026) · Česká a slovenská farmacie · doi:10.36290/csf.2026.020 · Cited by 1
Terui, S., Minami, T., Nakamura, K., & Terauchi, Y. (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.2.249 · Cited by 1
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
Chao, A. M., Asante, R., Sersah, M. E., Jahangir, U. A., Peary, A., & Kudaya, D. Q. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70162
Allaham, L., King, B. J., Ali, F., GUPTA, I., Metuku, R., Nieto, I., Lurie, A., Amer, F. N., Reddy, R., & Alzghoul, B. N. (2026) · Lung · doi:10.1007/s00408-026-00939-2
Moiz, A., Reynier, P., Tsoukas, M. A., Yu, O. H., Peters, T. M., Eisenberg, M. J., & Filion, K. B. (2026) · Systematic Reviews · doi:10.1186/s13643-026-03153-6
Ritzel, R. A., Davies, M. J., Hao, L., Ji, L., Lintu, M. K., Mabunay, A., Mauricio, D., & Bailey, T. S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01798-5
Predictors of treatment response to semaglutide for weight management
Tzoulis, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1893511
Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving
Habegger, K. M., Tomás, A., Chen, R., Harris, C., Roell, W. C., & Coşkun, T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1710843
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Stoicescu, L., Homorodean, C., Gligor, F. G., & Morgovan, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-120507
Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review
Abdalla, S. A. M., Gharbawi, L., Elshaikh, N., Omer, E. O. E., Osman, A. F. M., Ali, A. S. H., Mohamed, T. M. Y., & Alhajri, A. H. M. (2026) · Cureus · doi:10.7759/cureus.114454
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Murugadoss, K., Venkatakrishnan, A., & Soundararajan, V. (2026) · medRxiv · doi:10.64898/2026.04.11.26350687
BMI shouldn’t be the only way to assess who can access weight-loss drugs
Sturgiss, E. A., & Norman, K. (2025) · The Conversation · doi:10.64628/aa.cfv9wwte9
Pina, L., Chang, A., Wood, G. C., Nguyen-Lee, J. J., Horsley, R. D., Falvo, A. M., Mahan, M. E., Obradovic, V. N., Petrick, A. T., & Parker, D. M. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12417-6 · Cited by 3
Guo, A., Krishnan, S., Patel, J., Nayeri, R., Chatterjee, D., Srivastava, P. K., & Nayeri, A. (2026) · Next research. · doi:10.1016/j.nexres.2026.102044
Tangirala, S., Isaac, S., Gehad, Y., Roquefort, F., Gabrieli, P., Leong, A., Mercader, J. M., Sevilla-González, M. D. R., Baldini, F., Miller, G. W., et al. (2025) · medRxiv · doi:10.1101/2025.09.26.25336579
Tirzepatide and semaglutide: different twins?
Cesaro, A., Acerbo, V., & Calabrò, P. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag028
Dallal, R. M., Das, A., Pribitkin, E. A., Beekley, A. C., Tatarian, T., Malhotra, D. K., Harrison, T. D., & Yeo, C. J. (2026) · Annals of Surgery · doi:10.1097/sla.0000000000007039
Johansson, E., Wilding, J. P. H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner‐Rapuch, S., Annemans, L., & Bays, H. E. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646078 · Cited by 1
Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie
Busti, M. D., Canonico, M. E., Keramida, K., Palazzuoli, A., Kato, E. T., Sakata, Y., Alexy, T., Grupper, A., Nodari, S., Ojji, D. B., et al. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10627-1
Studio SURMONT 5 e differenze di genere nella risposta al trattamento dell’obesità
Velardi, V., Fabris, B., & Bernardi, S. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01725-7
Zheng, J., Yang, J., & Yang, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-105429 · Cited by 2
Fu, H., & Saltiel, A. R. (2026) · Cell Research · doi:10.1038/s41422-026-01271-3
Keyserling, T. C., Wu, Q., Ammerman, A. S., Berkowitz, S. A., Buse, J. B., Couper, D. J., Evenson, K. R., Hursting, S., Sotres‐Alvarez, D., Lyons, K. M., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.29006 · Cited by 1
Glucagon-like peptide-1 receptor agonists as metabolic adjuncts in immune-mediated skin disease
Lazarowitz, R., Saroufim, L., Sauder, M. B., Osman, M. S., Tardio, V., Litvinov, I. V., & Netchiporouk, E. (2026) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2026.02.047
Han, Y., Shon, J., & Park, Y. J. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2728313
Vásquez-Tirado, G. A., Villarreal-Jara, M., Meregildo-Rodríguez, E. D., & Quispe-Castañeda, C. V. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100697
Blathra, E., & Liberopoulos, E. N. (2025) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_16_25
Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials
Todd, M., Savage, P., Campbell, M., Hogg, M., McKane, M., & Menown, I. B. A. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03653-w · Cited by 1
Back to the Future: From Bariatric Surgery to Pharmacotherapy in Obesity Management
Akbaş, F. (2026) · Istanbul Medical Journal · doi:10.4274/imj.galenos.2026.280426
Kojima, T., Osaga, S., Aranishi, T., Fukuda, H., & Shingaki, T. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2655083
Ghusn, W., Fansa, S., Tama, E., Añazco, D., Espinosa, M. A., Villamarin, J. L., Cifuentes, L., Gala, K. S., Hurtado, M. D., & Acosta, A. J. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.02.006 · Cited by 3
Reitz, J., Rosoff, D. B., Pacher, P., & Lohoff, F. W. (2026) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2026.100793 · Cited by 1
Cardiovascular pharmacotherapy in 2025
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G., Drexel, H., Ferdinandy, P., Grove, E. L., Klingenberg, R., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag016 · Cited by 2
Palka, W., Moćko, P., Śladowska, K., Holko, P., & Kawalec, P. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-03006-y
Zidek, W. (2025) · Diabetes aktuell · doi:10.1055/a-2624-1018
Suchacki, K. J., Ramage, L. E., Boyle, L. D., Kwok, T. C., Blanco, G. R., Kelman, A., Gray, C. D., von Kriegsheim, A., Gregoriades, M., Oniscu, G. C., et al. (2026) · Journal of Translational Medicine · doi:10.1101/2025.08.24.671970
Kuryłowicz, A., & Czupryniak, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71226 · Cited by 3
Real world tirzepatide treatment for fatty liver disease
Maung, S. T., & Wong, V. W. (2026) · Hepatology International · doi:10.1007/s12072-026-11065-9
Agonists and Antagonists of the Human GIP Receptor
Kizilkaya, H. S., Gasbjerg, L. S., Holst, J. J., & Rosenkilde, M. M. (2026) · Wiley eBooks · doi:10.1002/9783527845408.ch2
Panhofer, P., Krzyzanowska-Mittermayer, K., & Rothe, S. (2026) · Deutsche Zeitschrift für Akupunktur · doi:10.1007/s42212-025-00797-8
Reopening the Energy Deficit: Beige Adipocytes in Weight Loss Therapy
Ussar, S. (2026) · Diabetes · doi:10.2337/dbi26-0019
Response to “The Challenge of Dose‐Specific Comparisons in Obesity Pharmacotherapy”
Lim, M. W., Gokhale, P., Akosah, A. A., & Zapata, L. V. (2026) · Obesity · doi:10.1002/oby.70297
Coprescribing GLP-1 Receptor Agonists and Lifestyle
Rockwell, M. S., Polk, E., & Mittendorf, C. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.6248
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
For Weight Loss: Why Do GLP-1 Agonists Work, and How Can We Make Them Work Better?
Giang, C., Meng, J., Mohammad, M. A., Liu, Z., Wu, X., & Zhu, Y. (2026) · Biology · doi:10.3390/biology15161395 · Cited by 1
Oral Incretin-Based Therapies for Weight Management
Cheng, H. E., Bonafede, M., & Shukla, A. P. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01456-6
Long-term management of body weight and physiological mechanisms of weight regain
Hu, T., & Bao, Y. (2026) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf062 · Cited by 1
Piguet, C. E. M., Nucci, R., & Beaudry, J. L. (2026) · The Journal of Physiology · doi:10.1113/jp291081 · Cited by 1
GLP-1 receptor agonists in pediatric obesity
Abodi, M., Agostoni, C. V., & Mazzocchi, A. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.06.010
Jóźwik-Szymańska, A., Kostecka, N., Mikula, L., Bogdan-Groszyk, Z., Szredzka, A., Kucharski, J., Makulec, A., Otrębska, K., & Lewandowska, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6514
Ciudin, A., Johansson, E., Zimner‐Rapuch, S., Dimitriadis, G. K., Bertrand, M., Curteis, T., Clark, L. J., Fan, L., Sapin, H., & Bergmann, J. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02229-6
Monteiro, M. P., Frutuoso, J. F., Pereira, S. S., Guimarães, M., & Monteiro, M. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1870008
Young, C. B., Rives, E., Gudzune, K. A., Jaeger, B. C., Simmons, C., White, B. N., Hooker, S. A., Horn, D. B., Young, D. R., Vesely, J. M., et al. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108219 · Cited by 4
Self-citationMihălțan, F.-D., Borcea, C.-I., & Constantin, A. A. (2026) · Life · doi:10.3390/life16050802
GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation
Cruz, P., Puebla-Huerta, A., Troncoso, M. F., Silva-Pavez, E., Hidalgo, Y., & Ahumada-Castro, U. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1826699
Obesity, lipids, inflammation, and healthy aging
Rikhi, R. R., & Shapiro, M. D. (2026) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2026.08.006
Practical use of GLP-1-based medications in obesity clinics
Jethwani, P. D., Hallock, R., & Griebeler, M. L. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2026.08.011
Corona, G., Sparano, C., Romeo, M., Sedigh, O., Bettocchi, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260045
Umińska, J. M., Ratajczak, J. M., Niezgoda, P., Gajda, R., Szarpak, Ł., Kubica, J., & Navarese, E. P. (2026) · Obesities · doi:10.3390/obesities6030038 · Cited by 3
Economic evaluations of antiobesity medications: A systematic literature review
Jurković, M., Fajkić, A., Faour, A. K., Momčilović, M., Turčić, P., & Belančić, A. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70825
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure
Nicze, M., Borówka, M., Dec, A., Bułdak, Ł., Bołdys, A., & Okopień, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062539 · Cited by 7
Tirzepatide vs. Semaglutide for Obesity Treatment
Muskiet, M. H. A., Winter, E. M., & Rensen, P. C. N. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510962
Cardiovascular-kidney-metabolic-syndrome: a modern view of the problem
Кanorskiy, S. G. (2025) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2025-6-3-6-16
Adipositas: neue medikamentöse Therapien
Seufert, J. (2026) · Nervenheilkunde · doi:10.1055/a-2939-1909
Fang, T.-J., Wang, C. C., Sun, J., & Han, C. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1844650
The Evolution of Medications for Obesity Management
Gill, J., & Sumithran, P. (2026) · JGH Open · doi:10.1002/jgh3.70466
Petersen, J., Merrild, C., Holm, S. K., Kurgan, N., Hassan, S., Mathiesen, C. V., Börchers, S., Svendsen, C., D’Anna, S., Andersen, N. R., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01603-y
Moiz, A., Filion, K. B., Samuels, A. E., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05519
Yakushevskaya, O. V. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-075
Barrett, P., Brooks, C. P., McCluskey, S., & Brown, A. (2026) · Journal of Eating Disorders · doi:10.1186/s40337-026-01634-6 · Cited by 1
Robinson, R., Sarkar, T. D., Moore, S., & Malhotra, A. (2026) · Current Sleep Medicine Reports · doi:10.1007/s40675-026-00373-z
Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes
Al-Nusair, M., Khurana, S., Eysha, M., Elchouemi, M., & Zaki, I. H. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02087-z
Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes
Chuan, F., Gao, Y., & Zhou, B. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2600572
Pereira, P. P. D. S., Nakata, K. C. D. F., Nakata, G. Y., Oliveira, L., Oliveira, H., Guenkka, T. M., Barreto, Z. Q., Teixeira, E. H. M., Pizzaro, C., & Cosme, A. K. D. S. (2026) · Research Square · doi:10.21203/rs.3.rs-9180565/v1
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Alkhateeb, F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02716-x
Aberle, J., Lautenbach, A., Meyhöfer, S., Menzen, M., Selig, L., Mai, K., Blüher, M., & Terkamp, C. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8270 · Cited by 2
Faut-il faire maigrir les patients ayant une insuffisance respiratoire chronique et une obésité ?
Borel, A., Suzeau, P., & Borel, J. (2025) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2025.06.004
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Anti-obesity medications for the management of obstructive sleep apnoea
Collings, T., & Outhoff, K. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.4699
Ahmed, M. (2025) · Journal of Prevention Diagnosis and Management of Human Diseases · doi:10.55529/jpdmhd.52.68.79
Feraco, A., Camajani, E., Muscogiuri, G., Barrea, L., Colao, A., & Caprio, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00695-7 · Cited by 2
Maqsood, A., Khan, A. R., Aaqil, S. I., Cheema, A. A. A., Ali, M., Jacob, J., Muhammad, N., & Siddiqi, A. K. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005191 · Cited by 2
Mackey, S., Egan, C., & Elkind-Hirsch, K. E. (2026) · Therapeutic Advances in Reproductive Health · doi:10.1177/26334941261481473
Dennard, E., Makres, K., Alibilli, A., Jain, V., Wang, A., Abim-Karmon, R., Criss, S., Hswen, Y., Nguyen, Q., Ratzki-Leewing, A., et al. (2025) · doi:10.2196/preprints.89732
Pozzi, E., Negri, F., Raffo, M., Boeri, L., Ventimiglia, E., d'Arma, A., Amodio, G., Pagliardini, L., Alfano, M., Montorsi, F., et al. (2026) · Andrology · doi:10.1111/andr.70275
Riesemann, S., Tenge, T., & Roth, S. (2026) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001644
Majanović, S. K., Belančić, A., Gkrinia, E. M. M., Božek, T., Štimac, I., & Ciudin, A. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102141
Fujishiro, M., Hagiwara, K., Nemoto, A., Kuroyanagi, H., Nosoko, M., Okamura, N., Kon, U., Uchida, H., Ogawa, K., & Ishihara, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1895420
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
Metadata
- Authors
- Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. P.
- Affiliations
- Weill Cornell Medicine (US)
- University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston
- Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin
- University of California, Los Angeles (US)
- Eli Lilly, Indianapolis
- Eli Lilly (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-07-03
- Volume
- 393
- Issue
- 1
- Pages
- 26-36
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4410277932
- Cited by
- 634
- References
- 40
- Citations by year
- 2026: 448 · 2025: 186
- FWCI
- 355.83
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eCommons (Cornell University) (submittedVersion, cc-by-nc-nd)
- Funders
- Eli Lilly and Company (NA)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- tirzepatide, semaglutide, obesity, weight loss, waist circumference, GLP-1 receptor agonists, GIP/GLP-1 receptor agonist, gastrointestinal adverse effects, non-diabetic obesity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Adult, Aged, Body Weight, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents, Maximum Tolerated Dose, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.